Hypersomnie

Hypersomnie, was ist das? Die exzessive Tagesschläfrigkeit ohne nächtliche Ursachen ist eine eigenständige Erkrankung und betrifft in der Regel eher jüngere Menschen, kann aber auch bis ins hohe Lebensalter auftreten.

• Literatur

• 1 Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
• 2 Herscovitch J, Broughton R. Sensitivity of the stanford sleepiness scale to the effects of cumulative partial sleep deprivation and recovery oversleeping. Sleep 1981; 4: 83-91.
• 3 Glenville M, Broughton R. Reliability of the Stanford Sleepiness Scale compared to short duration performance tests and the Wilkinson Auditory Vigilance Task. Adv Biosci 1978; 21: 235-244.
• 4 Carskadon MA, Dement WC, Mitler MM. et al. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986; 9: 519-524.
• 5 Danker-Hopfe H, Kraemer S, Dorn H. et al. Time-of-day variations in different measures of sleepiness (MSLT, pupillography, and SSS) and their interrelations. Psychophysiology 2001; 38: 828-835.
• 6 Chouvarda I, Rosso V, Mendez MO. et al. EEG complexity during sleep: on the effect of micro and macro sleep structure. Conf Proc IEEE Eng Med Biol Soc 2010; 2010: 5959-5962.
• 7 Guilleminault C, Phillips R, Dement WC. A syndrome of hypersomnia with automatic behavior. Electroencephalogr Clin Neurophysiol 1975; 38: 403-413.
• 8 Akerstedt T, Ingre M, Kecklund G. et al. Reaction of sleepiness indicators to partial sleep deprivation, time of day and time on task in a driving simulator – the DROWSI project. J Sleep Res 2010; 19: 298-309.
• 9 Kaplan KA, Itoi A, Dement WC. Awareness of sleepiness and ability to predict sleep onset: can drivers avoid falling asleep at the wheel?. Sleep Med 2007; 9: 71-79.
• 10 Akerstedt T, Hallvig D, Anund A. et al. Having to stop driving at night because of dangerous sleepiness. J Sleep Res 2013; 22: 380-388.
• 11 D’Alessandro R, Rinaldi R, Cristina E, Gamberini G, Lugaresi E. Prevalence of excessive daytime sleepiness an open epidemiological problem. Sleep 1995; 18: 389-391.
• 12 Pizza F, Contardi S, Mondini S. et al. Daytime sleepiness and driving performance in patients with obstructive sleep apnea: comparison of the MSLT, the MWT, and a simulated driving task. Sleep 2009; 32: 382-391.
• 13 Oudiette D, Leu S, Pottier M, Buzare MA, Brion A, Arnulf I. Dreamlike mentations during sleepwalking and sleep terrors in adults. Sleep 2009; 32: 1621-1627.
• 14 Young TB. Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence. J Clin Psychiatry 2004; 65 (Suppl. 16) 12-16.
• 15 Wing YK, Chen L. Cross-cultural epidemiology of daytime sleepiness: universality, diversity and definition issues. Sleep Med 2009; 10: 164-166.
• 16 Pelin Z, Guilleminault C, Risch N. et al. HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens 1998; 51: 96-100.
• 17 Nishino S, Ripley B, Overeem S. et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 39-40.
• 18 Mitler MM, Nelson S, Hajdukovic R. Narcolepsy. Diagnosis, treatment, and management. Psychiatr Clin North Am 1987; 10: 593-606.
• 19 Sansa G, Falup-Pecurariu C, Salamero M. et al. Non-random temporal distribution of sleep onset REM periods in the MSLT in narcolepsy. J Neurol Sci 2014; 341: 136-138.
• 20 Hong SC, Lin L, Jeong JH. et al. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. Sleep 2006; 29: 1429-1438.
• 21 Soehner AM, Kaplan KA, Harvey AG. Prevalence and clinical correlates of co-occurring insomnia and hypersomnia symptoms in depression. J Affect Disord 2014; 167: 93-97.
• 22 Coelho FM, Pradella-Hallinan M. et al. Prevalence of the HLA-DQB1*0602 allele in narcolepsy and idiopathic hypersomnia patients seen at a sleep disorders outpatient unit in Sao Paulo. Rev Bras Psiquiatr 2009; 31: 10-14.
• 23 Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics 2012; 9: 739-752.
• 24 Mignot E, Thorsby E. Narcolepsy and the HLA system. N Engl J Med 2001; 344: 692.
• 25 Weeß H-G. Kleine-Levin-Syndrom. Schlaf 2013; 2: 89-93.
• 26 Miglis MG, Guilleminault C. Kleine-Levin syndrome: a review. Nat Sci Sleep 2014; 6: 19-26.
• 27 Mayer G, Benes H, Young P. et al. Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study. J Sleep Res 2015; 24: 74-81.
• 28 Hinsch MC. Modafinil – unbedenkliche Anwendung als Neuroenhancer?. Schlaf 2015; 4: 100-101.
• 29 Vgontzas AN, Bixler EO, Kales A, Criley C, Vela-Bueno A. Differences in nocturnal and daytime sleep between primary and psychiatric hypersomnia: diagnostic and treatment implications. Psychosom Med 2000; 62: 220-226.
• 30 Lippert J, Halfter H, Heidbreder A. et al. Altered dynamics in the circadian oscillation of clock genes in dermal fibroblasts of patients suffering from idiopathic hypersomnia. PLoS One 2014; 9: e85255.
• 31 Nofzinger EA, Thase ME, Reynolds 3rd CF. et al. Hypersomnia in bipolar depression: a comparison with narcolepsy using the multiple sleep latency test. Am J Psychiatry 1991; 148: 1177-1181.
• 32 Wilhelm B. Pupillographie in der Schlaf- und Arbeitsmedizin. Schlaf 2014; 3: 206-209.
• 33 Orth M, Rasche K, Kotterba S. Schläfrigkeit im Straßenverkehr. Schlaf 2014; 3: 210-215.